Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Enterprise Value (2016 - 2025)

Karyopharm Therapeutics' Enterprise Value history spans 14 years, with the latest figure at -$50.9 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 53.14% year-over-year to -$50.9 million; the TTM value through Dec 2025 reached -$50.9 million, up 53.14%, while the annual FY2025 figure was -$50.9 million, 53.14% up from the prior year.
  • Enterprise Value reached -$50.9 million in Q4 2025 per KPTI's latest filing, down from -$43.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$43.5 million in Q3 2025 to a low of -$260.4 million in Q1 2023.
  • Average Enterprise Value over 5 years is -$133.3 million, with a median of -$146.1 million recorded in 2022.
  • Peak YoY movement for Enterprise Value: soared 82.14% in 2021, then plummeted 390.65% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$44.5 million in 2021, then crashed by 223.21% to -$143.8 million in 2022, then tumbled by 33.09% to -$191.4 million in 2023, then surged by 43.21% to -$108.7 million in 2024, then soared by 53.14% to -$50.9 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Enterprise Value are -$50.9 million (Q4 2025), -$43.5 million (Q3 2025), and -$47.9 million (Q2 2025).